J&J directors off the hook for quality meltdown; Man killed in India plant explosion;

> A judge has dismissed a lawsuit against Johnson & Johnson ($JNJ) directors brought by shareholders who accused them of ignoring indications of product manufacturing problems that eventually led to a host of product recalls. Article

> A man was killed and two more were injured when a vacuum cylinder exploded in a pharma manufacturing unit of Vidya Herbals in India. Story

> Failure to conduct any specific identity test of drug ingredients and to establish the reliability of supplier's analyses through periodic validation are among the violations described in a warning letter to Dental Technologies in Lincolnwood, IL. Warning Letter CHI-18-11

> Stirling pharma plant for sale in Nova Scotia: 46,000 square feet, GMP compliant, and with the unique capability to assist clients in bringing products from development through scale-up to commercial production. Story

> Toronto-based Patheon ($TSK:PTI) says the president of its North American operations, Peter Bigelow, will leave the company Nov. 1, to pursue other opportunities, but will remain a consultant as the company continues its drive to return to profitability. Article

> CMO Vetters has announced that its first U.S. site, a 24,000-square-foot plant in suburban Chicago, is fully operational. Release

> Sanofi's ($SNY) Pasteur unit, which acquired Shantha Biotechnics in 2009, will soon unveil a new vaccine manufacturing facility in Hyderabad. Story

> Yusen Logistics will provide international supply chain services for U.K. drugmaker ProStrakan. Report

Suggested Articles

Dr. Reddy’s says it has been told the FDA will not take regulatory action at its sterile formulations plant in Duvvada, Visakhapatnam.

The end is near for a GlaxoSmithKline OTC plant in Pennsylvania and its 260 employees. In fact, it has a date. 

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.